Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's amazing what shareholders will now settle for compared to five years ago. What happened to Double Digit Dreams? The time taken to get the company to this point has taken its toll on its people. The company needs a suitor with healthcare sales and a distribution infrastructure already in place. The ultimate question will be the price. One would have to expect that the lack of sales and the lack of company infrastructure would entice a potential suitor to try to lowball any offer. We would do the same thing if we were sitting on the side of the suitor. A dilemma: What happens if the company gets one offer, and that one offer is insulting to shareholders? What does the company do....settle for .50 to $1.50? A serious effort toward sales by current distributors would help. I will be pleasantly surprised if the EPA acquiesces given the lack of real-world testing.....unless of course the company has been testing the system in hospitals and just decided to withhold that material information from us.
Unfortunately, the developed world looks upon our healthcare regulatory bodies as the know-all and see-all Gods in spite of the drugs and devices that have been pulled from the marketplace over the years. So the Gods are human after all. The line can be drawn when devices are minimally invasive and exhibit little/no side effects. Asepticsure, when used properly by trained technicians, is such a device. The world needs to see log kill rates of this magnitude.
Gelati.....have you ever shown New Zealand healthcare officials the results of the 2013 Belleville test? I realize it's all the company has on which to hang its hat......but it's still better than nothing. As I stated the other day in a post, there is plenty of proof out there that many sovereign governments won't wait for the dinosaur to give a thumbs up if a little proof can be provided. Have you arranged to do any testing at all in NZ?
It's a similar tracking process, because of its easy ability to spread, to the way UNICEF, WHO, and Rotary have tackled the polio virus in the developing world: capture and quarantine. That's the name of the game. Rotary tells us that polio is now down to three countries with new cases: Nigeria, Afghanistan, and Pakistan.....and Nigeria has not had a new case in nine months. AS could be an absolute god-send to the developing world. Show those countries a little proof, and they won't wait for some lethargic dinosaur regulatory body over here to give a thumbs up. The needs of the people are too immediate.
Now, now, Gentlemen.........we have been waiting for news of a promotional dinner for the THREE YEARS that AS has been approved in Canada. Let's hope they have a huge celebration. I'll kick in a couple of bucks if asked...hahahahaha.
The news from Turkey is of monumental proportions. One would hope enough positive data could be collected from these machines alone to satisfy the FDA. GTHP, however, has never fully disclosed to shareholders what the FDA's problem is. My perception is that they're still butting heads over prior efficacy numbers. It's a serious concern. I try not to be a conspiracy theorist......but if the efficacy numbers really are as good as Guided says they are.......then the company has other problems. Maybe a few toes, belonging to the big boys, will be stepped on with approval in the area of pap smears, biopsies, etc. (Then why not just buy the company?) Maybe someone at Guided ticked off someone at the FDA. The bottom line is that the product either works 90+% of the time or it doesn't. I hope the new test results will overwhelmingly strengthen the case for approval.
Hi GOFOR......we could only hope our other "buddies" were as proactive as GTHP.
Greenwood, S.C.......home of the Swingin' Medallions. One would think Medizone could request a waiver from the EPA to eradicate E.Coli in that town. Of course we have all hoped for waivers in Dallas, Atlanta, etc., that never occurred. The rest of the world needs Asepticsure, yet we have no proof of it being introduced in most areas and have not had updates concerning New Zealand, Singapore, etc. for a very long time. Not every sovereign government awaits approval from U.S. regulatory bodies. Many opportunities have been squandered, but many opportunities remain. The patent clock, however, continues to tick.
Thanks for the feedback, Terry. Is MVPI's case THAT much stronger? Your thoughts are appreciated.
Slowly but surely GTHP is getting there. It would be a whole different ballgame if the procedure was being met with resistance in the developing world. It's not....it's actually being embraced.
Eli....see if I missed anything. Zoutman is listed as an "Honourary" member of IPAC. Wood Wyant is listed as a "Bronze" sponsor. Two other Monday "poster" presentations pop up for Zoutman under the headings of M37(Patient Room Cleaning Times in Canadian Acute Care Hospitals) and M38(Quality Improvement Initiatives in Acute Care Hospitals). I noticed that Clorox and 3M were listed as corporate sponsors. We all would wish Zoutman and Medizone could have been included in the oral presentation titled, "Wipe Out! Cleaning, Disinfection, and Sterilization". When one peruses the relevance of the bios of the major presenters (Zoutman is conspicuously absent, because, I guess, he is not an oral presenter at all), many of these people should be introduced to AS ASAP. Did I miss a reference to Zoutman as an oral presenter anywhere?
We speculate on this message board because, most of the time, we are given no other choice. Did the EPA ask for a testing sequence similar to what the company just announced......in order to grant an approval....or did the company initiate it on its own? It's a very fair question given we have received so little information on the most recent testing sequence. The problem (however negligent it was) with the peroxide supplier seems to be an issue easily corrected. We need to know what the current status is with the EPA.
The side effects being reported from the cervical cancer vaccines are serious. I don't know, however, how widespread they are. One would think that the market for LuViva in the U.S. could be enhanced simply because of the dangers of the vaccines.
One must wonder....if LuViva had been developed by big pharma, if we would even be having these discussions. I attended the meeting this morning and left it scratching my head. All the data shows 99% efficacy, according to CEO Cartwright. The FDA, evidently, just wants more of it. No other issues, old or new according to CEO Cartwright, exist. The FDA has allowed big pharma to bring out products so dangerous that they eventually were pulled from the marketplace. LuViva obviously works, has no side effects, and shows immediate results. It makes one wonder if, a few years ago, someone at Guided really ticked off someone at the FDA.....and/or if this test really steps on the toes of big pharma that bad.
We're really good at waiting, aren't we, GO!
Would someone like to take a stab at the meaning of "various complex, but solvable regulatory requirements"?....as worded in the latest Chairman's Letter. Uh....what are the OTHER issues besides the hydrogen peroxide origin? Chronologically, it seems that the term "complex" requirements has come up since the latest round of tests were completed....yet we have not been told the results of the latest round of testing from the last six months. Again, I am referring to material information about the development of Medizone's lead product. Who can wager a good guess as to what is really happening? It's almost June. I think we're looking into 2016 before we receive any final answers....by which time, by the way, management might be out of PPLs.
I did attend. According to the moderator, over fifty people were in attendance. Just two of us, however, asked questions. The margins on the equipment sales improved (they needed to). New markets continue to open up. Cartwright seemed upbeat when I questioned him about progress getting the FDA to better interpret the 2013 test results. They re expecting approval, IMHO, but did vaguely mention the possibility of initial restrictions with the approval. No one asked him about it.
Ozone therapy is approved in at least ten states, and one can buy ozone machines for various purposes all over the internet.
We focused on the hydrogen peroxide issue(self included) and didn't ask (and weren't offered)for the actual test results from early winter. Does the EPA have a problem with the results themselves or was the concern the ingredients used to derive the results? It's almost mid-May. Where is the winter's requested test results?
GTHP should be fortunate that any outside government and/or company has bought a system at all without first having our almighty FDA's seal of approval. It's good to see foreigners bucking the old system. The darn thing just might work.
Thanks for the YOU TUBE presentation. Other presentations on those pages relate to the dangers of the cervical cancer vaccines finally being brought forward. I don't think GTHP ever thought LuViva would be a serious product here because of the two vaccines. Having viewed the related videos this morning, I am thinking LuViva may have a huge market right here in the U.S. Given the seriousness of the vaccines' side effects, I continute to scratch my head as to why LuViva is still not on the market here.
This hydrogen peroxide issue is material information related to the development of a lead product and obviously has caused further delays. Was the peroxide issue listed as part of the original test protocol? Did the EPA not bother to inform Medizone, until just recently, that it had this requirement? Did Medizone ignore an original written protocol? Will Medizone have to repeat all of the EPA required tests to see if it obtains the same results using a registered peroxide solution? What kind of a chemical composition difference could there be between a registered and a non-registered solution? Is it a proof of purity issue?
Uh.....how long has the company known it was using a "non-registered" brand of hydrogen peroxide?
Who will contact Jennifer Rodgers and let her know about AS?
Well....the GTHP people have been asked for more tests twice, so we truly know what they have been going through. I just don't think Guided would be this proactive around the globe if its ventures into Turkey and Africa had not been successful. What the company did was bring in a seasoned, new CEO who understood international markets and international regulatory situations. What a difference.
Well.....my goodness.....Hi, Go! A retired plastic surgeon in Atlanta, who is a high school buddy of mine, brought this little company to my attention 3-4 years ago. You can see a huge difference in style compared to the "other" company we keep a collective eye on. Guided has annual meetings, quarterly conference calls, and their top people have their own money in this thing. Market cap is miniscule, so the need to raise funds and increase shares is there periodically. The company justifies it by being extremely proactive around the world. I still think that Mr. Cartwright, with his connections from his years at Abbott and GE, will have prospective buyers in the wings when the FDA comes through. The EU approval was based on the U.S. test, yet the FDA, according to Cartwright, has been struggling with the interpretation of the data. Hopefully, with positive results coming in from several markets in the developing world, the FDA won't be able to hold this one back anymore. The reports from Emory, Johns Hopkins, etc. are glowing. Remember C3? It's going to be a LuViva distributor in Canada.
Eli......thanks for outlining three areas of focus pointing to material information involving the company. The company has provided no update on required testing given the length of time between E.P.A. responses. We're paying for a law firm in D.C. to monitor EPA activity. What are we missing? Where's KSA? Where is testing being done? What's the real benefit of the continued research expenditures? When shareholder values continue to be diluted internally, don't said shareholders deserve a more detailed explanation as to why? Where is management supposedly "working hard" to make sure the company succeeds?
It's not a drug. It's an immediate result diagnostic test for cervical cancer that, in many cases, will negate the need for biopsies and pap smears. The potential market is a question you could pose to management during the May conference call. When countries as large as Mexico see cervical cancer as the #1 cause of death in women of child bearing age, the market should be huge.
Hardly.......penny land always is a momentum play driven by news. The Indonesia and China news wore off before an FDA nod came, so some people took profits between 13-14 and 24 cents. I suspect we'll receive more news about entrance into other countries before an FDA nod comes. Evaluating test results from all over the globe now can do nothing but enhance the company's position re the agency.
Nice close today. Selling volume seems to have dried up after two days. Maybe...just maybe.....FDA personnel are interpreting GTHPs data the way GTHP intended for the agency to interpret it. No one at GTHP ever explained well why the turndown occurred in 2013. Gene Cartwright said the main problem the FDA was having involved interpretation of the data. These agencies are dinosaurs. The EPA, which has had efficacy problems of its own, currently is delaying market approval on a decontamination system for hospitals, clinics, vets offices, cruise ships, etc. that is producing 99.99999 log kill rates.
Well.......Hi Dianne. The deadline was supposed to be Feb. 15. Bill Wells informed us that the FDA was still reviewing new data. LuViva has a much larger market potential than NEPH's lead product. I certainly expect LuV to carry GTHP well beyond NEPH's .65 share price. We just have to wait it out.
Hi Dianne. After the long approval delays, the company only has been able to muster 1 3/4 million in revenues out of its lead product to sustain a stock price of .65. NEPH needs to have its filter business kick in bigtime, at some point, or things just aren't looking that good.
If we see a nod from the FDA plus a large order, hold onto your hats: small capitalization, unknown (but not for much longer), noninvasive important product with global demand. I am looking for $3 to $5 in six months. Pent up demand will explode. We forget the global control the FDA has....and that control is archaic, inefficient, and way too political. Look at how many products from big pharma have turned out to be harmful over the last decade.
Canada is a tough nut to crack. It's easier to get approval for a product than it is to gain acceptance. I know that sounds weird, but Canadian socialism rules the roost. Doctors who complete med school in Canada often come to the U.S. to practice. Others quit med school in mid-stream because they realize the government isn't going to allow them a chance to make a decent living in order to pay back their loans. Providing testing and independent test results, to provincial governments that actually are interested in the test, is a big feather in the company's cap. Canada, like Kenya and Guatemala, has a few million people living in tough, remote areas where medical care is sparse.
Trader......LuViva is a real product that really works, is non-invasive, and is really needed throughout the world.....something quite unusual for pennyland, isn't it! If only the real products could be hyped like the scams, eh?
Eventually running out of authorized shares and needing shareholder approval, via a shareholder meeting, to authorize more.
Positives: Small float, institutional cluelessness, need for the product, quality of product, global approvals in place, prospect for merger. I really think institutional awareness would have Guided back up to a buck by now. Hundreds of penny issues with larger floats are out there with nowhere near the product potential as GTHP.....but they're hyped (marketed) a lot better.
It would be easier to wait patiently if we knew the company was testing AS (like it said it was going to do in Canada last year). The continued silence might tell us that the current quarter's 10Q is going to look like the last several quarters' 10Qs: nothing but hand-sitting going on here. Funds are running low again....no revenues from countries where AS has been approved. We inch closer to a mandatory shareholder meeting, an event really hampering my ability to wait patiently.
Possible......but......the Indonesia and China announcements could have been enough news to create some fresh buying at distressed prices. We'll see.
Nice volume at mid-afternoon: 1,225,000 shares. Crappy day in the market. GTHP stock absorbing sells very well at .22
We're two months past the last FDA deadline but were informed about it by Bill Wells at Guided. He said the FDA was still analyzing data. The company probably has sent the FDA data from all over the world now. I have never fully understood why the initial 2013 rejection happened. I personally would trust scientists at Johns Hopkins and Emory long before I would trust government bureaucrats attached at the hip to the big boys.